Eudralex Volume 3 CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products
Title:
Eudralex Volume 3 CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products
Origin/Publisher:
European Commission Enterprise and Industry DG, BREY 13/ 092, B - 1049 Brussels (Belgium), http://ec.europa.eu/enterprise/
Document Type:
Draft Guideline
Content:
The composition of ATMPs may include components of human origin (either as active ingredient, excipients, or raw materials used in their manufacture) and, therefore, the risk of transmitting CJD or vCJD agents has to be considered. Current status of related guidelines